Skip to main content

Table 2 Comparison between liver function enzymes, oxidant/antioxidant status markers and genotoxicity markers within the four studied groups

From: Therapeutic effects of N-acetylcysteine against malathion-induced hepatotoxicity

Measured parameters Group 1 Group 2 Group 3 Group 4
ALT (U/l) 15.88 ± 2.83 15.88 ± 3.26 58.04 ± 17.74ab 26.16 ± 6.61abc
AST (U/l) 17.84 ± 2.37 17.32 ± 2.97 51.88 ± 11.17ab 26.08 ± 6.42abc
ALP (U/l) 126.68 ± 4.8 127.85 ± 7.02 288.78 ± 32.84ab 164.97 ± 17.88abc
LDH (U/l) 88.48 ± 7.94 80.2 ± 5.24 178.76 ± 32.22ab 113.8 ± 12.53abc
GSH (mmol/gm) 58.96 ± 3.99 59.94 ± 4.15 27.8 ± 8.38ab 47.07 ± 8.36abc
MDA (nmol/gm) 5.94 ± 1.89 5.94 ± 0.64 34.26 ± 11.31ab 14.69 ± 5.39abc
TAC (nmol/gm) 25.52 ± 3.09 29.78 ± 4.63a 16.32 ± 4.97ab 22.56 ± 5.47bc
Apoptosis gene “Bax” 1.02 ± 0.02 1.02 ± 0.02 5.58 ± 1.64ab 2.82 ± 0.81abc
Antipoptosis gene “Bcl-2” 1.01 ± 0.02 1.01 ± 0.01 0.35 ± 0.17ab 0.71 ± 0.19abc
DNA fragmentation 1.92 ± 0.34 1.88 ± 0.36 33.75 ± 10.81ab 3.66 ± 2.38c
  1. Values are represented in mean ± standard deviation (S.D)
  2. Group 1: control (negative), group 2: NAC only, group 3: malathion only, group 4: malathion plus NAC
  3. aSignificant compared to corresponding value in group 1 at P < 0.05
  4. bSignificant compared to corresponding value in group 2 at P < 0.05
  5. cSignificant compared to corresponding value in group 3 at P < 0.05